NextCure (NXTC) Operating Expenses (2018 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at NextCure was $43.9 million, down 31.3% year-over-year; for FY2025, it came in at $57.62 million, down 3.6% from FY2024.

• Annual Operating Expenses has declined for three consecutive years, with a five-year compound annual growth rate of -2.0% (FY2020 to FY2025).
• In prior years, NextCure's Operating Expenses was $59.75 million in FY2024 (-11.7%), $67.64 million in FY2023 (-10.9%), $75.91 million in FY2022 (+7.3%) and $70.77 million in FY2021 (+11.3%).
• Quarterly Operating Expenses has run from a low of $8.95 million in Q3 2025 to a high of $27.29 million in Q2 2025 over five years.
• On a year-over-year basis, Operating Expenses has declined in each of the last four quarters, with an average decline of 15.0% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q2 2025, with growth of 65.5%; the weakest was Q2 2026, with a decline of 44.7%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $10.11 million (Q1 2026), $9.76 million (Q4 2025) and $8.95 million (Q3 2025).